[AKRX] Akorn, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 21.71 Change: 0.63 (2.99%)
Ext. hours: Change: 0 (0%)

chart AKRX

Refresh chart

Strongest Trends Summary For AKRX

AKRX is in the long-term up 276% in 25 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Akorn, Inc. manufactures and markets diagnostic and therapeutic ophthalmic pharmaceuticals, niche hospital drugs, and injectable pharmaceuticals in the United States and internationally. It offers products in various areas, including ophthalmology, antidotes, anti-infectives, pain management, anesthesia, vaccines, and others. The company operates in three segments: Ophthalmic, Hospital Drugs & Injectables, and Contract Services. The Ophthalmic segment markets diagnostic products, such as mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, angiography dyes, and others for use in the office setting; therapeutic products, including antibiotics, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines, and anti-edema medications to wholesalers, chain drug stores, and other national account customers; non-pharmaceutical products comprising artificial tear solutions, preservative-free lubricating ointments, and eyelid cleansers; and over-the-counter dry eye and

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS1.68 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 151.41% Sales Growth - Q/Q71.65% P/E19.93
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA1.85% ROE9.14% ROI
Current Ratio3.68 Quick Ratio2.71 Long Term Debt/Equity3.1 Debt Ratio0.35
Gross Margin50.18% Operating Margin16.31% Net Profit Margin5.96% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities972.31 M Cash From Investing Activities-966.54 M Cash From Operating Activities30.92 M Gross Profit128.38 M
Net Profit34.23 M Operating Profit71.91 M Total Assets1.91 B Total Current Assets494.33 M
Total Current Liabilities134.16 M Total Debt1.12 B Total Liabilities1.52 B Total Revenue227.83 M
Technical Data
High 52 week33.56 Low 52 week3.33 Last close3.64 Last change-5.94%
RSI48.76 Average true range0.32 Beta0.93 Volume2.35 M
Simple moving average 20 days-0.15% Simple moving average 50 days-30.37% Simple moving average 200 days-72.33%
Performance Data
Performance Week4.6% Performance Month-17.65% Performance Quart-41.85% Performance Half-74.07%
Performance Year-89.13% Performance Year-to-date7.37% Volatility daily5.48% Volatility weekly12.26%
Volatility monthly25.12% Volatility yearly87.01% Relative Volume219.78% Average Volume3.71 M
New High New Low

News

2020-05-28 11:14:57 | WeWork Board Factions Head for Clash Over New Directors

2020-05-26 12:42:08 | Akorn, Inc. -- Moody's downgrades Akorn's PDR to D-PD following Chapter 11 filing

2020-05-22 13:37:14 | Akorn Seeks Bankruptcy After Failed Takeover, FDA Warnings

2020-05-21 12:21:00 | Akorn Files Chapter 11 After Failure to Be Acquired

2020-05-21 08:01:32 | The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive

2020-05-21 07:56:09 | Akorn Plummets 27% In Pre-Market On Bankruptcy Filing

2020-05-20 23:52:00 | Akorn to Use Voluntary Chapter 11 Process to Position Business for Long-Term Success

2020-05-20 20:12:53 | Forescout sues Advent to complete $1.9 billion merger

2020-05-11 17:14:47 | Akorn Provides First Quarter 2020 Results

2020-04-27 18:17:00 | Enphase Energy and Paylocity Set to Join S&P MidCap 400; Core Laboratories and Meredith to Join S&P SmallCap 600

2020-04-07 11:24:49 | WeWork Directors Sue SoftBank Over Decision to Abandon Deal

2020-04-02 15:59:45 | Bed Bath sues 1-800-Flowers for trying to renege on deal over COVID-19

2020-04-01 06:20:00 | Akorn Provides Update on Sale Process

2020-02-29 07:20:45 | US$4.00: That's What Analysts Think Akorn, Inc. Is Worth After Its Latest Results

2020-02-26 16:58:47 | Akorn Provides Fourth Quarter and Full Year 2019 Results

2020-02-19 09:55:02 | Akorn AKRX to Report Q4 Earnings: What's in the Cards?

2020-02-12 17:29:00 | Akorn Announces New Extension of Standstill with Lenders and Agrees to Pursue a Sale of its Business

2020-02-10 07:00:00 | Akorn Continues Negotiations with Lenders

2020-01-31 07:12:43 | How Many Akorn, Inc. NASDAQ:AKRX Shares Did Insiders Buy, In The Last Year?

2020-01-14 12:41:12 | Akorn, Inc. -- Moody's announces completion of a periodic review of ratings of Akorn, Inc.

2019-12-19 09:26:02 | Akorn Enters Oversold Territory

2019-12-18 14:52:00 | Akorn's stock extends plunge toward record low after disclosing it was exploring a bankruptcy

2019-12-16 07:51:52 | Akorn Announces Extension of Standstill Agreement

2019-12-11 13:54:53 | Is Akorn, Inc. AKRX Going To Burn These Hedge Funds ?

2019-12-02 08:00:43 | Easy Come, Easy Go: How Akorn NASDAQ:AKRX Shareholders Got Unlucky And Saw 90% Of Their Cash Evaporate

2019-11-28 09:00:02 | Akorn AKRX Moves to Strong Buy: Rationale Behind the Upgrade

2019-11-26 08:36:01 | Generic Drugmakers Gain as Price-Fixing Probe Nears an End

2019-11-19 16:54:22 | Teva, Bausch Could Be Next to File for Bankruptcy

2019-11-12 08:27:01 | The Zacks Analyst Blog Highlights: Forterra, Barrett Business, Chuy's, Akorn and Quanex

2019-11-11 07:03:12 | 5 Small-Cap Stocks Outpacing the Broader Market in 2019

2019-11-07 08:22:01 | New Strong Buy Stocks for November 7th

2019-11-05 19:00:00 | Akorn to Present at the Credit Suisse Healthcare Conference

2019-10-31 23:04:35 | Edited Transcript of AKRX earnings conference call or presentation 31-Oct-19 2:00pm GMT

2019-10-31 08:35:12 | Akorn AKRX Q3 Earnings and Revenues Top Estimates

2019-10-31 07:00:05 | Akorn Provides Preliminary Third Quarter 2019 Results

2019-10-24 10:32:02 | Will Akorn AKRX Report Negative Earnings Next Week? What You Should Know

2019-10-17 09:00:01 | All You Need to Know About Akorn AKRX Rating Upgrade to Buy

2019-10-15 07:50:13 | The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J Earnings

2019-10-14 16:25:00 | Akorn Receives FDA Approval for Betamethasone Dipropionate Lotion USP Augmented, 0.05%

2019-10-14 13:05:00 | Akorn to Report Third Quarter 2019 Financial Results and Host Conference Call

2019-09-29 08:36:40 | Should You Be Concerned About Akorn, Inc.'s NASDAQ:AKRX Historical Volatility?

2019-08-26 13:35:36 | Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.15%

2019-08-14 15:30:05 | Is Akorn NASDAQ:AKRX A Risky Investment?

2019-08-05 16:15:04 | Edited Transcript of AKRX earnings conference call or presentation 1-Aug-19 1:00pm GMT

2019-08-02 07:24:08 | Akorn AKRX Q2 2019 Earnings Call Transcript

2019-08-01 08:55:12 | Akorn AKRX Reports Q2 Loss, Tops Revenue Estimates

2019-07-25 10:33:02 | Analysts Estimate Akorn AKRX to Report a Decline in Earnings: What to Look Out for

2019-07-11 16:32:15 | Akorn to Report Second Quarter 2019 Financial Results and Host Conference Call

2019-07-09 08:02:30 | See what the IHS Markit Score report has to say about Akorn Inc.

2019-06-28 07:00:00 | Akorn Announces Launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5%